Reata, AIM, Fire

Thanks in large part to its giant deal with Abbott Laboratories for bardoxolone, Reata Pharmaceuticals Inc. thinks it has a big enough war chest to not only complete clinical testing of the compound in its first indication, but also to build a commercial organization in time for a 2013 launch in the U.S.

Moreover, the company hopes to have enough cash left over to move multiple second-generation molecules into the clinic for a host of inflammation-mediated disorders...